Ebola vaccine development plan: ethics, concerns and proposed measures

设为首页

收藏本站

网站地图 | English | 公务邮箱

About the library

Background
History
Leadership
Organization

Readers' Guide

Opening Hours
Collections
Help Via Email

Publications

Electronic Information Resources

Ebola vaccine development plan: ethics, concerns and proposed measures

详细信息查看全文

作者：Morenike Oluwatoyin Folayan ; Aminu Yakubu ; Bridget Haire…
关键词：Ebola ; Vaccine ; Healthcare workers ; TRIPS ; Public dialogue ; Standard of care ; Myths
刊名：BMC Medical Ethics
出版年：2016
出版时间：December 2016
年：2016
卷：17
期：1
全文大小：481 KB
参考文献：1.Polesky A, Bhatia G. Ebola hemorrhagic fever in the era of bioterrorism. Semin Respir Infect. 2003;18:206–15.
2.World Health Organisation. Statement on the WHO Consultation on potential Ebola therapies and vaccines. Retrieved 29th November 2014 from: http://www.who.int/mediacentre/news/statements/2014/ebola-therapies-consultation/en/ . Accessed 29th November 2014.
3.Lamontagne F, Clément C, Fletcher T, Jacob ST, Fischer 2nd WA, Fowler RA. Doing today’s work superbly well--treating Ebola with current tools. N Engl J Med. 2014;371:1565–6.CrossRef
4.Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, Sprecher A. Ebola virus disease in West Africa--clinical manifestations and management. N Engl J Med. 2014;371:2054–7.CrossRef
5.Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, Colubri A, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med. 2014;371:2092–100.CrossRef
6.Ansumana R, Jacobsen KH, Sahr F, Idris M, Bangura H, Boie-Jalloh M, et al. Ebola in Freetown area, Sierra Leone--a case study of 581 patients. N Engl J Med. 2015;372:587–8.CrossRef
7.Bah EI, Lamah MC, Fletcher T, Jacob ST, Brett-Major DM, Sall AA, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med. 2015;372:40–7.CrossRef
8.Decker BK, Sevransky JE, Barrett K, Davey RT, Chertow DS. Preparing for critical care services to patients with Ebola. Ann Intern Med. 2014;161:831–2.CrossRef
9.Kreuels B, Wichmann D, Emmerich P, Schmidt-Chanasit J, de Heer G, Kluge S, et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med. 2014;371:2394–401.CrossRef
10.O’Hare B. Weak health systems and Ebola. Lancet Glob Health. 2015;3:e71–2.CrossRef
11.Gostin LO. Ebola: towards an International Health Systems Fund. Lancet. 2014;384(9951):e49–51.CrossRef
12.Wesley PJ. Liberia’s Ebola Epidemic: Did the Government Fall Asleep at the Wheel? Cultural Anthropology Online. 7th October 2014. http://www.culanth.org/fieldsights/602-liberias-ebola-epidemic-did-the-government-fall-asleep-at-the-wheel . Accessed 22nd April, 2015.
13.Ammann T. Ebola in Liberia: a threat to human security and peace. Cultural Anthropology Online. 7th October 2014. http://www.culanth.org/fieldsights/597-ebola-in-liberia-a-threatto-human-security-and-peace . Accessed 22nd April, 2015.
14.Sayegh J: Ebola and the Health Care Crisis in Liberia. Cultural Anthropology Online 2014; 7th October 2014. http://www.culanth.org/fieldsights/595-ebola-and-the-health-care-crisis-in-liberia . Accessed 22nd April, 2015
15.Tucker B. Beats, rhymes and Ebola. Cultural Anthropology Online, 7th October 2014, http://www.culanth.org/fieldsights/592-be . Accessed 22nd April, 2015.
16.Cox E, Borio L, Temple R. Evaluating Ebola Therapies - the case for RCTs. N Engl Med. 2014;371(25):2350–2351.CrossRef
17.Cohen J, Kupferschmidt K. Infectious Diseases. Ebola vaccine trials raise ethical issues. Science. 2014;346:289–90.CrossRef
18.Bellan SE, Pulliam JR, Dushoff J, Meyers LA. Ebola virus vaccine trials: the ethical mandate for a therapeutic safety net. BMJ. 2014;349:7518s.CrossRef
19.Kanapathipillai R, HenaoRestrepo AM, Fast P, Wood D, Dye C, Kieny MP, et al. Ebola vaccine: an urgent international priority. N Engl J Med. 2014;371:2249–51.CrossRef
20.Rid A, Emanuel EJ. Ethical considerations of experimental interventions in the Ebola outbreak. Lancet. 2014;384:1896–9.CrossRef
21.Hayden EC. Ethical dilemma for Ebola trials: Public-health officials split on use of control groups in tests of experimental treatments. Nature. 2014;515:177–8.CrossRef
22.Adebamowo C, Bah-Sow O, Binka F, Bruzzone R, Caplan A, Delfraissy JF, et al. Randomised controlled trials for Ebola: practical and ethical issues. Lancet. 2014;384:1423–4.CrossRef
23.Dawson L. Not All RCTs are created equal: lessons from early AIDS trials. Am J Bioeth. 2015;15:45–7.CrossRef
24.Caplan AL. Morality in a time of Ebola. Lancet. 2015;385(9971):e16–7.CrossRef
25.Caplan AL, Plunkett C, Levin B. Selecting the right tool for the job. Am J Bioeth. 2015;15(4):4–10.CrossRef
26.Folayan MO, Haire B, Peterson K, Yakubu A, Brown B. Stakeholder engagement and Ebola Virus Disease therapy research. BMC Public Health (in Press).
27.Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, et al. Efficacyand effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386:857.CrossRef
28.Fenner F, Henderson D, Arita I, Ladnyi I. Smallpox and its eradication. Retrived August 1st 2015 from: http://whqlibdoc.who.int/smallpox/9241561106.pdf . Accessed 29th November 2014.
29.Medicin San Frontieres (MSF). We’re getting closer to an Ebola vaccine. Field News. Retrieved August 1st 2015 from: http://www.msf.org.au/from-the-field/field-news/field-news/article/were-getting-closer-to-an-ebola-vaccine.html . Accessed 29th November 2014.
30.Centers for Disease Control and Prevention (CDC). Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE) Q&A. Retrieved September 1st 2015 from: http://www.cdc.gov/vhf/ebola/strive/qa.html . Accessed 29th November 2014.
31.National Institutes of Health (NIH). Ebola vaccine trial opens in Liberia. Study led by Liberia-NIH partnership will test two experimental vaccines. Retrieved September 1st 2015 from:http://www.niaid.nih.gov/news/newsreleases/2015/Pages/PREVAIL.aspx . Accessed 29th November 2014.
32.World Health Organization (WHO). Ebola vaccines, therapies, and diagnostics. Questions and Answers.6 July 2015. Retrieved 2nd September 2015 from: http://www.who.int/medicines/emp_ebola_q_as/en/ . Accessed 29th November 2014.
33.Friedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141–5.CrossRef
34.Satalkar P, Elger BE, Shaw DM: Prioritising healthcare workers for Ebola treatment: treating those at greatest risk to confer greatest benefit. Dev World Bioeth 2015, 8731. doi:10.1111/dewb.12079
35.Macklin R. The Ethics of the Ebola Outbreak: Who Should Receive Experimental Treatment? http://www.huffingtonpost.com/ruth-macklin/the-ethics-of-the-ebola-o_b_5698128.html . Accessed 19tn April, 2015.
36.Degeling C, Johnson J, Mayes C. Impure politics and pure science: efficacious Ebola medications are only a palliation and not a cure for structural disadvantage. Am J Bioeth. 2015;15:43–5.CrossRef
37.Scoones I, Forster P. One world, one health? Rural 21. 2009;43:22–4.
38.Folayan MO, Haire B. Prioritization of healthcare workers for experimental Ebola therapeutic would exacerbate existing inequalities; DWB (in Press).
39.Yakubu A, Folayan MO, Sani-Gwarzo N, Nguku P, Peterson K, Brandon B. The Ebola outbreak in Western Africa-ethical obligations for care. J Med Ethics 2014, September 9, 10.1136/medethics-2014-102434 .
40.Breman JG, Johnson KM. Ebola then and now. N Engl J Med. 2014;371:1663–6.CrossRef
41.Guimard Y, Bwaka MA, Colebunders R, Calain P, Massamba M, De Roo A, et al. Organization of patient care during the Ebola hemorrhagic fever epidemic in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis. 1999;179:S268–73.CrossRef
42.Lipsitch M, Longini IM. Vaccine testing Ebola and beyond. Science. 2015;348:46–8.CrossRef
43.The Ebola Response Anthropology Platform. Anthropology and Ebola clinical research. http://www.ebola-anthropology.net/wp-content/uploads/2015/01/Clinical-Trials-Anthropology-Platform-Working-Document-070115.pdf . Accessed 22nd April, 2015.
44.Daniels N. Justice, health and healthcare. Am J Bioeth. 2001;1(2):2–16.CrossRef
45.Edmond MB, Diekema DJ, Rerencevich N. Ebola Virus Disease and the need for new personal protection equipment. JAMA. 2014;312:2495–6.CrossRef
46.Shuchman M. Sierra Leone doctors call for better Ebola care for colleagues. Lancet. 2014;384:e67.CrossRef
47.Kass N. Ebola, ethics, and public health: what next. Ann Intern Med. 2014;161:744–5.CrossRef
48.Ukpong M, Peterson K. Oral Tenofovir Controversy II: Voices from the field: a series of reports of the oral tenofovir trials from the perspectives of active community voices engaged on the field in Cambodia, Cameroon, Nigeria, Thailand and Malawi. New HIV Vaccine and Microbicide Advocacy Society. 2009. Retrieved 19th November 2014 from: http://www.nhvmas-ng.org/publication/TDF2.pdf . Accessed 29th November 2014.
49.Molyneux CS, Geissler PW. Ethics and the ethnography of medical research in Africa. Soc Sci Med. 2008;67:685–95.CrossRef
50.Zvonareva O, Engel N, Ross E, Berghmans R, Dhai A, Krumeich A. Engaging diverse social and cultural worlds: perspectives on benefits in international clinical research from South African communities. Dev World Bioeth. 2015;15:8–17.CrossRef
51.UNAIDS/WHO. Ethical considerations in biomedical HIV prevention trials. UNAIDS/WHO guidance document. http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/unaidspublication/2012/jc1399_ethical_considerations_en.pdf . Accessed 19th April, 2015.
52.Miller L, Folayan M, Allman D, Nkala B, Kasirye LM, Mingote LR, et al. How ethical is your clinical trial? Int J ClinPract. 2010;64:1179–82.
53.Etokidem AJ. Wondifon: Myths and misconceptions as barriers to uptake of immunization. Vaccine Vaccination. 2013;4:7.
54.DeStefano F, Chen RT. Autism and measles-mumps-rubella vaccination: controversy laid to rest? CNS Drugs. 2001;15:831–7.CrossRef
55.World Health Organisation. Global vaccine safety: six common misconceptions about immunization. http://www.who.int/vaccine_safety/initiative/detection/immunization_misconceptions/en/index6.html . Accessed 19th April, 2015.
56.Kochhar S, Rath B, Seeber LD, Rundblad G, Khamesipour A, Ali M. Introducing new vaccines in developing countries. Expert Rev Vaccines. 2013;12:1465–78.CrossRef
57.Braka F, Asiimwe D, Soud F, Lewis RF, Makumbi I, Gust D. A qualitative analysis of vaccine safety perceptions and concerns among caretakers in Uganda. Matern Child Health J. 2012;16:1045–52.CrossRef
58.Chakrapani V, Newman PA, Singhal N, Jerajani J, Shunmugam M. Willingness to participate in HIV vaccine trials among men who have sex with men in Chennai and Mumbai, India: a social ecological approach. PLoS One. 2012;7:e51080.CrossRef
59.Udell C. Ebola, snakes and witchcraft: Stopping the deadly disease in its tracks in West Africa. International Federation of Red Cross and Red Crescent Societies. http://www.ifrc.org/en/news-and-media/news-stories/africa/sierra-leone/ebola-snakes-and-witchcraft-stopping-the-deadly-disease-in-its-tracks-in-west-africa-66215/ . Accessed 22nd April, 2015.
60.Reno W. Ironies of post-cold war structural adjustment in Sierra Leone. Rev Afr Polit Econ. 1996;23(67):7–18.
61.Outram Q. Its terminal either way: an analysis of armed conflict in Liberia 1989–1996. Rev Afr Polit Econ. 1997;24(73):355–71.
62.allAfrica. Health workers battling Ebola stigma in Ebola-stricken Liberia. Retrieved 23rd December, 2014 from: http://allafrica.com/stories/201410060668.html . Accessed 29th November 2014.
63.Torjesen I. Two doctors die from Ebola and lives of others under threat in West Africa. BMJ. 2014;349:4895.CrossRef
64.Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: Epidemiology and prevention in developing countries. World J Hepatol. 2012;4:74–80.CrossRef
65.World Medical Association. Declaration of Helsinki. 2008.
66.CIOMS. International ethical guidelines for biomedical research involving human subjects. 2002.
67.Milstien J, Kaddar M. Managing the effects of TRIPS on availability of priority vaccines. Bull World Health Organ. 2006;84:360–5.CrossRef
68.Saez C. WHO: Fight Ebola now, solve patent issues later. Intellectual Property Watch. 6th September, 2014. Retrieved 8th November 2014 from: http://www.ip-watch.org/2014/09/06/who-fight-ebola-now-solve-patent-issues-later/ . Accessed 29th November 2014.
69.Roos R. FDA, industry officials vow to minimize barriers to Ebola vaccines. University of Minnesota Centre for Infectious Disease Research and Policy. 5th November, 2014. Retrieved 8th November 2014 from: http://www.cidrap.umn.edu/news-perspective/2014/11/fda-industry-officials-vow-minimize-barriers-ebola-vaccines . Accessed 29th November 2014.
70.Danzon PM, Towse A. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int J Health Care Finance Econ. 2003;3:183–205.CrossRef
71.Lopert R, Lang DL, Hill SR, Henry DA. Differential pricing of drugs: a role for cost-effectiveness analysis? Lancet. 2002;359:2105–7.CrossRef
72.Nasiru SG, Aliyu GG, Gasasira A, Aliyu MH, Zubair M, Mandawari SU, et al. Breaking community barriers to polio vaccination in Northern Nigeria: the impact of a grass roots mobilization campaign (Majigi). Pathog Glob Health. 2012;106:166–71.CrossRef
作者单位：Morenike Oluwatoyin Folayan (1)
Aminu Yakubu (2)
Bridget Haire (3)
Kristin Peterson (4)

1. Institute of Public Health and Department of Child Dental Health, Obafemi Awolowo University, Ile-Ife, Nigeria
2. National Health Research Ethics Committee, Federal Ministry of Health, Federal Secretariat, Abuja, Nigeria
3. Kirby Institute for Infection in Society, UNSW, Australia
4. Department of Anthropology, University of California, Irvine, CA, USA
刊物主题：Ethics; Philosophy of Medicine; Theory of Medicine/Bioethics;
出版者：BioMed Central
ISSN：1472-6939

文摘

Background The global interest in developing therapies for Ebola infection management and its prevention is laudable. However the plan to conduct an emergency immunization program specifically for healthcare workers using experimental vaccines raises some ethical concerns. This paper shares perspectives on these concerns and suggests how some of them may best be addressed.